DelveInsight’s “Chemotherapy Induced Nausea and Vomiting (CINV)- Market Insights, Epidemiology and Market Forecast-2023” Report provides an overview of the disease and global market size of the Chemotherapy Induced Nausea and Vomiting (CINV) for the United States, EU5 (France, Germany, Italy, Spain, UK) and Japan. It also includes historical and forecasted epidemiological data for the Incident cases of Chemotherapy Induced Nausea and Vomiting (CINV) from 2013-2023.
Chemotherapy-induced nausea and vomiting (CINV) are both severe side effects of cancer treatment. CINV is a condition which makes a patient uncomfortable and has to be dealt properly as many patients delay their chemotherapy cycles or even refuse further treatment due to fear from future nausea and vomiting. Also, due to nausea and vomiting induced by chemotherapy, patients can’t get nutrition properly and lose their energy and may become weak which may hinder the further chemotherapy cycles as patient wouldn’t be physically string to bear the chemotherapy side-effects.
According to DelveInsight, the global market for Chemotherapy Induced Nausea and Vomiting (CINV) is estimated to be USD XX Million by 2023 at a CAGR of 8.32 % for the forecast period i.e., 2013-2023.
The report is built using data and information sourced from proprietary databases, primary and secondary research and in-house Forecast model analysis by Publisher team of industry experts.
Scope
The report will help in developing business strategies by understanding the trends shaping and driving the Chemotherapy Induced Nausea and Vomiting (CINV) market.
Organize sales and marketing efforts by identifying the best opportunities for Chemotherapy Induced Nausea and Vomiting (CINV) in US, Europe (Germany, Spain, Italy, France and United Kingdom) and Japan.
To understand the future market competition in the 7MM market of Chemotherapy Induced Nausea and Vomiting (CINV) and Insightful review of the key market drivers and barriers.
To understand the regulatory scenario in major markets.
The Report also covers the detailed historical and forecasted Chemotherapy Induced Nausea and Vomiting (CINV)market covering United States, Europe (Germany, Spain, Italy, France and United Kingdom) and Japan from 2013-2023.
'
Report Introduction
Chemotherapy Induced Nausea and Vomiting (CINV) Market Overview at a Glance
Global Market Size of CINV in 2016
Global Market Size of CINV in 2023
Chemotherapy Induced Nausea and Vomiting (CINV)
Overview
Types of CINV
Risk Factors
Pathophysiology of CINV
Epidemiology and Patient Population
Assumptions and Caveats
United States
Incident Cases of Chemotherapy Induced Nausea and Vomiting in United States
Europe
Germany
Incident Cases of Chemotherapy Induced Nausea and Vomiting in Germany
Italy
Incident Cases of Chemotherapy Induced Nausea and Vomiting in Italy
Spain
Incident Cases of Chemotherapy Induced Nausea and Vomiting in Spain
France
Incident Cases of Chemotherapy Induced Nausea and Vomiting in France
United Kingdom
Incident Cases of Chemotherapy Induced Nausea and Vomiting in United Kingdom
Japan
Incident Cases of Chemotherapy Induced Nausea and Vomiting in Japan
Treatment Algorithm
Emetic Risk Category of Chemotherapeutic Agents
Emetogenic potential of Intravenous anti-neoplastic agents
Emetogenic potential of oral anti-neoplastic agents
NHS Guidelines for Chemotherapy Induced Nausea and Vomiting (CINV)
Summary of Anti-emetics prescribing
First line Anti-emetics
Second Line Anti-emetics
Standard Anti-Emetic Regimes for Haematology Oncology
MASCC/ESMO Antiemetic Guideline 2016
Acute Chemotherapy Induced Nausea and Vomiting Guidelines
Delayed Chemotherapy Induced Nausea and Vomiting Guidelines
Guidelines for Other types of CINV cases
Guidelines for CINV in Children
ASCO Guidelines for treatment of CINV
NCCN Guidelines for Chemotherapy Induced Nausea and Vomiting
High emetic risk Intravenous chemotherapy- acute and delayed emesis prevention
Moderate emetic risk Intravenous chemotherapy- acute and delayed emesis prevention
Low and minimal emetic risk Intravenous chemotherapy- acute and delayed emesis prevention
Oral chemotherapy- emesis prevention
Breakthrough treatment for CINV
Anticipatory Emesis Prevention/treatment
Marketed Drugs
List of Marketed Drugs
Generic Drugs and their Efficacy
Marketed Drugs Presence
Sustol: Heron Therapeutics
Drug Description
Mechanism of Action
Regulatory Milestones
Advantages & Disadvantages
Safety and Efficacy of Sustol
Product Profile
Sancuso: Kyowa Kirin Inc
Drug Description
Mechanism of Action
Regulatory Milestones
Advantages & Disadvantages
Safety and Efficacy of Sancuso
Product Profile
Aloxi: Helsinn Birex Pharmaceuticals Ltd.
Drug Description
Mechanism of Action
Regulatory Milestones
Advantages & Disadvantages
Safety and Efficacy of Aloxi
Product Profile
Akynzeo: Helsinn Birex Pharmaceuticals Ltd.
Drug Description
Mechanism of Action
Regulatory Milestones
Advantages & Disadvantages
Safety and Efficacy of Akynzeo
Product Profile
Emend: Merck Sharp and Dohme Ltd
Drug Description
Mechanism of Action
Regulatory Milestones
Advantages & Disadvantages
Safety and Efficacy of Emend
Product Profile
Varubi: Tesaro, Inc.
Drug Description
Mechanism of Action
Regulatory Milestones
Advantages & Disadvantages
Safety and Efficacy of Varubi
Product Profile
Ivemend: Merck Sharp & Dohme Ltd
Drug Description
Mechanism of Action
Regulatory Milestones
Advantages & Disadvantages
Safety and Efficacy of Ivemend
Product Profile
Kytril: Hoffmann-La Roche
Drug Description
Mechanism of Action
Regulatory Milestones
Advantages & Disadvantages
Safety and Efficacy of Kytril
Product Profile
Syndros: Insys Therapeutics
Drug Description
Mechanism of Action
Regulatory Milestones
Advantages & Disadvantages
Safety and Efficacy of Syndros
Product Profile
Other Approved Drugs for Chemotherapy induced Nausea and Vomiting (CINV)
Zofran: Novartis
Zuplenz: Par Pharmaceutical, Inc.
Emerging Therapies
Pipeline Drugs
Pipeline Drugs Results
Cinvanti: Heron Therapeutics, Inc.
Clinical Development
Advantages & Disadvantages
Product Profile
Akynzeo(IV): Helsinn Birex Pharmaceuticals Ltd.
Advantages & Disadvantages
Product Profile
Sancuso: Kyowa Kirin Inc
Drug Description
Advantages & Disadvantages
Product Profile
Rolapitant(IV): Tesaro, Inc.
Drug Description
Advantages & Disadvantages
Product Profile
Market Size
Assumptions and Caveats
Forecasting Events
Global CINV: Country-Wise Market Analysis
United States
Europe
Japan
Market Drivers
Market Barriers
Unmet Needs
Appendix
Report Methodology
Consulting Services
Disclaimer
About DelveInsight
Table 1: Incident Cases of Chemotherapy Induced Nausea and Vomiting in United States (2013-2023)
Table 2: Incident Cases of Chemotherapy Induced Nausea and Vomiting in Germany (2013-2023)
Table 3: Incident Cases of Chemotherapy Induced Nausea and Vomiting in Italy (2013-2023)
Table 4: Incident Cases of Chemotherapy Induced Nausea and Vomiting in Spain (2013-2023)
Table 5: Incident Cases of Chemotherapy Induced Nausea and Vomiting in France (2013-2023)
Table 6: Incident Cases of Chemotherapy Induced Nausea and Vomiting in United Kingdom (2013-2023)
Table 7: Incident Cases of Chemotherapy Induced Nausea and Vomiting in Japan (2013-2023)
Table 8: List of Marketed Drugs for Chemotherapy Induced Nausea and Vomiting
Table 9: Generic Drugs and their Efficacy for Chemotherapy Induced Nausea and Vomiting
Table 10: Marketed Drugs Presence for Chemotherapy Induced Nausea and Vomiting
Table 11: List of Pipeline Drugs for Chemotherapy Induced Nausea and Vomiting
Table 12: Results of Pipeline Drugs for Chemotherapy Induced Nausea and Vomiting
Table 13: Global Market Size of CINV in USD, Million (2013-2023)
Table 14: United States Market Size of CINV in USD, Million (2013-2023)
Table 15: Europe Market Size of CINV in USD, Million (2013-2023)
Table 16:JapanMarket Size of CINV in USD, Million (2013-2023)
